REGISTERED NUMBER: 15899957 (England and Wales)

Unaudited Financial Statements

for the Period 15 August 2024 to 31 December 2025

for

Flobiotech Limited

Page

Balance Sheet

1

Notes to the Financial Statements

3

FIXED ASSETS

Investments

4

28,382

CURRENT ASSETS

Debtors

5

460,335

Cash at bank

183,493

643,828

CREDITORS

Amounts falling due within one year

6

3,663

NET CURRENT ASSETS

640,165

TOTAL ASSETS LESS CURRENT LIABILITIES

668,547

CAPITAL AND RESERVES

Called up share capital

7

25,119

Share premium

665,214

Retained earnings

(21,786

)

SHAREHOLDERS' FUNDS

668,547

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 May 2026 and were signed on its behalf by:

L Galera - Director

1.	STATUTORY INFORMATION

Flobiotech Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

15899957

Registered office:

27 Old Gloucester Street

London

United Kingdom

WC1N 3AX

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these financial statements.

Reporting Period

These financial statements prepared for the period from 15 August 2024 to 31 December 2025 are the first financial statements of the company.

Financial Instruments

All of the financial instruments of the company are basic and the company has elected to apply the provisions of Section 11 "Basic Financial Instruments of FRS 10" to all its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instruments.

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

Cash and cash equivalents

Cash and cash equivalents comprise cash balances and call deposits..

Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Preparation of consolidated financial statements

The financial statements contain information about Flobiotech Ltd as an individual company and do not

contain consolidated financial information as the parent of a group. The company is exempt under

Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial

statements.

Investments in subsidiaries

Fixed assets investments relate to the company's holdings in its subsidiaries. Subsidiaries are entities in which Flobiotech Ltd holds more than half of the voting rights or has the ability to direct the financial and operating principles followed.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL.

4.	FIXED ASSET INVESTMENTS

Shares in

group

undertaking

£

COST

Additions

28,382

At 31 December 2025

28,382

NET BOOK VALUE

At 31 December 2025

28,382

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Flobiotech GMBH

Registered office: Switzerland

Nature of business: Scientific Research

%

Class of shares:

holding

Ordinary

100.00

Flobiotech SARL

Registered office: France

Nature of business: Scientific Research

%

Class of shares:

holding

Ordinary

100.00

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Amounts owed by group undertakings

459,407

Other debtors

928

460,335

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Trade creditors

963

Other creditors

2,700

3,663

7.	CALLED UP SHARE CAPITAL

£

Ordinary Share Capital

Issued and fully paid

Ordinary A Shares

24,829

Ordinary B Shares

200

Deferred Shares

90

Share Premium

665,214

690,333

During the year, the company issued 24,829,186 Ordinary A shares of £0.001 each, 200 Ordinary B shares of £1 each and 89,600 Deferred shares of £0.001 each. These issuances increased share capital by £24,729, £200, and £90 respectively.

The shares were issued at a premium, resulting in total share premium of £665,214, which has been recognised in the share premium account. These shares were fully paid.

8.	JOINT ULTIMATE CONTROLLING PARTY

The joint ultimate controlling parties are Dr Florence Clavaguera and Mr Loic Galera.